Patents for A61P 35 - Antineoplastic agents (221,099)
04/2007
04/12/2007WO2007041294A2 Methods for sensitizing cancer cells to inhibitors
04/12/2007WO2007040231A1 Quinazoline derivative and pharmaceutical
04/12/2007WO2007040212A1 Neuronal differentiation inhibitor peptide and use thereof
04/12/2007WO2007040123A1 Method for detection of human precursor t cell and precursor b cell
04/12/2007WO2007040105A1 Method for production of t cell population
04/12/2007WO2007039919A1 Crystalline forms of anastrozole
04/12/2007WO2007039752A1 Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
04/12/2007WO2007039716A1 T cell epitopes from the 5t4 tumor associated antigen and their use in treatment of cancer
04/12/2007WO2007039404A1 Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles
04/12/2007WO2007039231A2 Method of producing a modified (poly)peptide
04/12/2007WO2007039170A1 Antagonists of topoisomerase activity and their use in inhibiting pathological conditions
04/12/2007WO2007039129A1 Combination
04/12/2007WO2007038874A1 Grape seed extract and its constituents for use as cyp2a6 inhibitors
04/12/2007WO2007038869A1 Aptamers comprising arabinose modified nucleotides
04/12/2007WO2007020222A3 Pharmaceutical composition containing as active substance a protein fraction extracted from oviparous embryos at the cell differentiation stage and preparation process thereof
04/12/2007WO2007017585A3 Novel camptothecin analogues compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds
04/12/2007WO2007016385A3 Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators
04/12/2007WO2007015175A3 Use of pp-1 inhibitors to prevent missplicing events
04/12/2007WO2007014335A3 Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
04/12/2007WO2007011759A3 Inhibitors of mitotic kinesin
04/12/2007WO2007009720A3 Prodrugs of pyrazoline compounds, their preparation and use as medicaments
04/12/2007WO2006131515A3 Stabilised il-21 compositions
04/12/2007WO2006125921A3 Antibody or antibody fragment coupled with an immunogenic agent
04/12/2007WO2006125640A3 Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
04/12/2007WO2006125531A3 Thienopyridines
04/12/2007WO2006124813A3 Substituted 7, 8-dihydro-1h-pyrimido [4,5-b] [1,4] diazepin-4-amines as?kinase inhibitors
04/12/2007WO2006116451A3 Antibodies with immune effector activity and that internalize in endosialin-positive cells
04/12/2007WO2006032704A3 Diagnostic compounds for targeting a chemokine receptor
04/12/2007WO2005075460A3 Pyrrolopyrimidine derivatives for treating proliferative diseases
04/12/2007US20070082957 2-chloro-5-(3-oxopropyl)-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; P2X7 receptor antagonists; inflammatory, immune or cardiovascular diseases
04/12/2007US20070082921 Quinazoline derivatives as antitumor agents
04/12/2007US20070082906 1-(1-{4-[3-(1,3-oxazol- 2-yl)-6-phenyl-1,2,4- triazin-5- yl]benzyl}piperidin-4- yl)-1,3-dihydro-2H- benzimidazol-2-one; inhibit activity of a serine, threonine protein kinase; hyperproliferative disorders, restenosis, inflammation, autoimmune diseases, allergy, asthma
04/12/2007US20070082872 Indole-containing compounds with anti-tubulin and vascular targeting activity
04/12/2007US20070082860 Hla-a24-restricted cancer antigen peptides
04/12/2007US20070082847 Variants of vascular endothelial cell growth factor, their uses, and processes for their production
04/12/2007US20070082846 Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
04/12/2007US20070082391 Modified CEA Nucleic Acid and Expression Vectors
04/12/2007US20070082382 Development of human monoclonal antibodies and uses thereof
04/12/2007US20070082362 Modified soluble t cell receptor
04/12/2007US20070082357 Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme
04/12/2007US20070082341 Human phospholipases
04/12/2007US20070082334 Nucleotide and protein sequence of mammastatin and methods of use
04/12/2007US20070082075 Traditional chinese medicine preparation for treatment of tumor and method of making and using same
04/12/2007US20070082041 Topical delivery of codrugs
04/12/2007US20070082001 Novel engineered superantigen for human therapy
04/12/2007US20070081991 Compositions and methods for modulation of immune responses
04/12/2007US20070081974 Antibody targeting osteoclast-associated protein
04/12/2007US20070081942 Gene differentially expressed in breast and bladder cancer, and encoded polypeptides
04/12/2007US20070081941 F-18 Labeled Amino Acid Analogs
04/12/2007DE112005000737T5 Mit Heparansulfat-Zuckerketten modifizierte Heparin-bindende Proteine, Verfahren zur Erzeugung derselben und Arzneimittel, welche dieselben enthalten With heparan sulfate sugar chains modified heparin-binding proteins, methods for producing the same and pharmaceutical compositions containing the same
04/12/2007CA2624882A1 Pyrazolopyrimidines as protein kinase inhibitors
04/12/2007CA2624513A1 Combination
04/12/2007CA2624354A1 Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
04/12/2007CA2624253A1 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones
04/12/2007CA2624155A1 Method of producing a modified (poly)peptide
04/12/2007CA2624141A1 Quinazoline derivative and pharmaceutical
04/12/2007CA2623822A1 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
04/12/2007CA2623818A1 Aptamers comprising arabinose modified nucleotides
04/12/2007CA2623735A1 Method for production of t cell population
04/12/2007CA2622673A1 Sulphonylpyrroles and use thereof as inhibitors of hdac s
04/12/2007CA2621326A1 Conserved membrane activator of calcineurin (cmac), a novel therapeutic protein and target
04/12/2007CA2605781A1 Antigen binding molecules having modified fc regions and altered binding to fc receptors
04/11/2007EP1772517A2 DSP-3 dual specificity phosphatase
04/11/2007EP1772514A2 Manipulation of tissue or organ type using the notch pathway
04/11/2007EP1772462A2 Steroid sulfamates, method for the production and use thereof
04/11/2007EP1772452A2 Matrix metalloproteinase inhibitors and uses thereof
04/11/2007EP1771481A2 Novel anti-igf-ir antibodies and uses thereof
04/11/2007EP1771469A1 Use of llt1 and/or cd161 for modulating the activity of cells of the immune system
04/11/2007EP1771452A2 Inhibitors of 5'-methylthioadenosine phosphorylase and 5'methylthioadenosine/s-adenosylhomocysteine nucleosidase
04/11/2007EP1771443A1 Quinoline thiazolinones with cdk1 antiproliferative activity
04/11/2007EP1771413A2 Indole, benzofuran and benzothiphene derivatives as selective androgen receptor modulators (sarms)
04/11/2007EP1771207A2 Methods for treating cancer using agents that inhibit wnt16 signaling
04/11/2007EP1771181A2 Phosphole derivatives complexed with metals, and pharmaceutical uses thereof
04/11/2007EP1771179A2 COMPOSITIONS COMPRISING 5-ALPHA REDUCTASE INHIBITORS, AND SERMs AND METHODS OF USE THEREOF
04/11/2007EP1771178A1 Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies
04/11/2007EP1771177A2 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
04/11/2007EP1771174A1 Method for treating abnormal cell growth
04/11/2007EP1771172A2 Treatment of tumours
04/11/2007EP1771167A2 Histone deacetylase inhibitors
04/11/2007EP1771166A2 Rxr antagonists in the treatment of inflammatory diseases
04/11/2007EP1771154A1 Galenic applications of self-emulsifying mixtures of lipidic excipients
04/11/2007EP1511759A4 Modulators and inhibitors of fibroblast growth factor receptor 5-polypeptides and gene expression thereof.
04/11/2007EP1499595B1 Amonafide salts
04/11/2007EP1435985B1 Medicament containing activated antithrombin iii
04/11/2007EP1353952B1 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
04/11/2007EP1351938B1 Phenyl derivatives
04/11/2007EP1341767B1 Imidazole and benzimidazole caspase inhibitors and uses thereof
04/11/2007EP1313725B1 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
04/11/2007EP1175227B1 Monoclonal antibody directed against cells of human renal cell carcinoma
04/11/2007EP1147093B1 Substituted bicyclic derivatives useful as anticancer agents
04/11/2007EP1054894B1 Breast cancer resistance protein (bcrp) and the dna which encodes it
04/11/2007EP1054683B1 Modified heat shock protein-antigenic peptide complex
04/11/2007EP1021197B1 Implants comprising combinations of allogeneic cells for use in cancer treatment
04/11/2007EP1015439B1 Prenyl transferase inhibitors
04/11/2007EP0961780B1 Protein markers for lung cancer and use thereof
04/11/2007EP0950656B1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
04/11/2007EP0787122B1 Calcium receptor-active compounds
04/11/2007CN1946727A (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents
04/11/2007CN1946725A Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
04/11/2007CN1946697A Substituted pyrazoline compounds for reducing triglycerides in blood